DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,623 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,294,236 | 0.0% | 5,183 | 0.0% | 0.21% | 0.0% |
Q1 2024 | $1,294,236 | +10.1% | 5,183 | +2.0% | 0.21% | +1.0% |
Q4 2023 | $1,175,967 | -39.7% | 5,083 | -35.4% | 0.21% | -45.1% |
Q3 2023 | $1,950,967 | +48.1% | 7,864 | +43.3% | 0.38% | +55.3% |
Q2 2023 | $1,316,982 | +15.4% | 5,487 | +10.9% | 0.24% | -31.1% |
Q1 2023 | $1,141,545 | +19.9% | 4,946 | +36.5% | 0.35% | +16.4% |
Q4 2022 | $951,858 | +67.0% | 3,623 | +64.1% | 0.30% | +35.7% |
Q3 2022 | $570,000 | +4.8% | 2,208 | +2.8% | 0.22% | -28.2% |
Q2 2022 | $544,000 | -14.3% | 2,147 | -0.7% | 0.31% | -3.7% |
Q1 2022 | $635,000 | -12.7% | 2,163 | -2.1% | 0.32% | -23.6% |
Q4 2021 | $727,000 | -5.6% | 2,209 | -12.7% | 0.42% | +20.5% |
Q3 2021 | $770,000 | -31.4% | 2,529 | -39.5% | 0.35% | -28.3% |
Q2 2021 | $1,122,000 | -8.3% | 4,180 | -23.1% | 0.49% | -6.3% |
Q1 2021 | $1,223,000 | -7.3% | 5,433 | -8.6% | 0.52% | -14.9% |
Q4 2020 | $1,320,000 | +72.8% | 5,942 | +67.5% | 0.62% | +37.5% |
Q3 2020 | $764,000 | +26.7% | 3,548 | +4.0% | 0.45% | +17.6% |
Q2 2020 | $603,000 | +26.7% | 3,411 | -0.7% | 0.38% | +10.4% |
Q1 2020 | $476,000 | -10.5% | 3,436 | -0.9% | 0.34% | +35.3% |
Q4 2019 | $532,000 | +10.1% | 3,466 | +3.6% | 0.26% | -4.9% |
Q3 2019 | $483,000 | 0.0% | 3,346 | -1.0% | 0.27% | -4.6% |
Q2 2019 | $483,000 | +7.1% | 3,379 | -1.0% | 0.28% | +1.4% |
Q1 2019 | $451,000 | +45.0% | 3,414 | +13.3% | 0.28% | +22.6% |
Q4 2018 | $311,000 | -5.2% | 3,014 | 0.0% | 0.23% | +5.1% |
Q3 2018 | $328,000 | +15.1% | 3,014 | +4.4% | 0.22% | +1.4% |
Q2 2018 | $285,000 | +8.4% | 2,886 | +7.4% | 0.21% | +5.5% |
Q1 2018 | $263,000 | +16.4% | 2,686 | +10.4% | 0.20% | +21.1% |
Q4 2017 | $226,000 | +7.1% | 2,434 | -0.9% | 0.17% | -1.8% |
Q3 2017 | $211,000 | -4.1% | 2,455 | -5.7% | 0.17% | -7.1% |
Q2 2017 | $220,000 | -17.0% | 2,604 | -16.1% | 0.18% | -20.5% |
Q1 2017 | $265,000 | +31.8% | 3,104 | +21.3% | 0.23% | +34.7% |
Q3 2016 | $201,000 | -65.9% | 2,559 | -66.8% | 0.17% | -52.1% |
Q2 2016 | $590,000 | +14.3% | 7,704 | +41.7% | 0.36% | +6.9% |
Q1 2016 | $516,000 | +6.0% | 5,436 | +3.6% | 0.33% | +19.4% |
Q4 2015 | $487,000 | +22.1% | 5,247 | +12.0% | 0.28% | +5.7% |
Q3 2015 | $399,000 | +15.0% | 4,685 | +15.7% | 0.26% | +30.2% |
Q2 2015 | $347,000 | +8.8% | 4,049 | +7.6% | 0.20% | +4.1% |
Q1 2015 | $319,000 | – | 3,763 | – | 0.19% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |